197142-34-0

Usage

Uses

Used in Pharmaceutical Industry:
N-Boc-L-trans-4,5-methanoproline is used as a pharmaceutical intermediate for the synthesis of various drugs and medications. Its carboxylic acid derivative nature allows it to be a key component in the development of new pharmaceutical compounds, contributing to the advancement of medical treatments.
As a pharmaceutical intermediate, N-Boc-L-trans-4,5-methanoproline plays a crucial role in the synthesis of complex drug molecules, enabling the creation of novel therapeutic agents with improved efficacy and reduced side effects. Its versatility in chemical reactions and compatibility with various synthetic routes make it a valuable asset in the development of innovative pharmaceutical products.

Upstream product

• 1208008-34-7 (3S)-3-((tert-butyldiphenylsilyloxy)methyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1312338-82-1 D-cis-4,5-methanoprolineamide methanesulfonic acid salt 
• 132974-83-5 (5S)-5-[[(tert-butyldiphenylsilyl)oxy]methyl]pyrrolidin-2-one 
• 1208008-33-6 (3S)-tert-butyl 3-(tert-butyldiphenylsiloxymethyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate 
• 17342-08-4 (S)-Pyroglutaminol 
• 7149-65-7 ethyl (S)-pyroglutamate 
• 98-79-3 L-Pyroglutamic acid 
• 197142-32-8 3-(tert-butyldiphenylsilanyloxymethyl)-2-azabicyclo[3.1.0]-hexane-2-carboxylic acid tert-butyl ester 
• 138629-30-8 (S)-tert-butyl 2-((tert-butyldiphenylsilyloxy)methyl)-5-oxopyrrolidine-1-carboxylate 
• 197142-33-9 3-hydroxymethyl-2-azabicyclo[3.1.0]hexane-2-carboxylic acid tert-butyl ester 

Downstream Products

• 361440-69-9 L-trans-4,5-methanoprolineamide TFA salt 
• 1180671-44-6 C₁₉H₂₂BrNO₅ 
• 1228554-11-7 C₁₈H₂₂BrNO₅ 
• 1180671-56-0 (1R,3S,5R)-tert-butyl 3-(5-(4-bromophenyl)-1H-imidazol-2-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate 
• 1250941-14-0 (lR,3S,5R)-3-(2-(3-bromophenyl)-2-oxoethyl) 2-tert-butyl 2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate 
• 197142-33-9 3-hydroxymethyl-2-azabicyclo[3.1.0]hexane-2-carboxylic acid tert-butyl ester 
• 1250941-17-3 (lR,3S,5R)-tert-butyl 3-(4-(3-bromophenyl)-lH-imidazol-2-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate 
• 1446082-01-4 C₄₉H₅₁N₇O₆ 
• 1373165-37-7 C₂₁H₂₅IN₄O₃ 
• 1373165-38-8 C₂₁H₂₄ClIN₄O₃ 
• 1373165-39-9 C₂₇H₃₇BN₄O₅ 
• 214193-12-1 (1R,3S,5R)-2-azabicyclo[3.1.0]hexane-3 -carboxylic acid 
• 1250941-34-4 dimethyl (1,2-ethynediylbis(3,1-phenylene-1H-imidazote-4,2-diyl(2S)-2,1-pyrrolidinediyl((1S)-0.122-oxo-1-(tetrahydro-2H-pyran-4-yl)-2,1-ethanediyl)))biscarbamate 
• 1250941-20-8 C₃₈H₄₄N₆O₄ 

Relevant academic research and scientific papers

SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS

The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.

Structural Properties and Stereochemically Distinct Folding Preferences of 4,5-cis and trans-Methano- L -Proline Oligomers: The Shortest Crystalline PPII-Type Helical Proline-Derived Tetramer

The synthesis, structural properties, and folding patterns of a series of L-proline methanologues represented by cis- and trans-4,5-methano-L-proline amides and their oligomers are reported as revealed by X-ray crystallography, circular dichroism measurements, and DFT calculations. We disclose the first example of a crystalline tetrameric proline congener to exhibit a polyproline II helical conformation. Experimental evidence of PPII-type helical arrangement (both in solution and in the solid state) of cis-4,5-methano-L-proline oligomers is supported by theoretical calculations reflecting the extent of n→π? stabilization of the trans-amide conformation.

A scalable synthesis of (1R,3S,5R)-2-(tert-butoxycarbonyl)-2-azabicyclo[3. 1.0]hexane-3-carboxylic acid

A stereoselective and scalable synthesis of (1R,3S,5R)-2-(tert- butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (3a) is described. Key to the success of the devised route was the realization that the stereoselectivity of a cyclopropanation ste

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C INHIBITOR COMPOUNDS

Compounds of Formula (I) and (II) wherein R1, R2, R3, R6, A and A' are defined herein. The compounds are useful as inhibitors of the function of NS5A protein encoded by HCV for the treatment of hepatitis C viral infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

BI-1H-BENZIMIDAZOLES AS HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.